Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Friedreich Ataxia | 67 | 2025 | 75 | 22.630 |
Why?
|
Tomography, X-Ray Computed | 240 | 2025 | 2535 | 22.430 |
Why?
|
Lung Diseases, Interstitial | 85 | 2025 | 616 | 11.880 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 97 | 2025 | 985 | 11.160 |
Why?
|
Pulmonary Emphysema | 63 | 2024 | 275 | 10.000 |
Why?
|
Idiopathic Pulmonary Fibrosis | 58 | 2025 | 636 | 7.680 |
Why?
|
Lung | 135 | 2025 | 3930 | 6.440 |
Why?
|
Pulmonary Fibrosis | 31 | 2025 | 386 | 5.340 |
Why?
|
Iron-Binding Proteins | 30 | 2025 | 40 | 4.800 |
Why?
|
Lung Diseases | 29 | 2023 | 742 | 4.130 |
Why?
|
Emphysema | 16 | 2024 | 109 | 3.660 |
Why?
|
Smoking | 58 | 2024 | 1501 | 3.570 |
Why?
|
Radiography, Thoracic | 25 | 2024 | 168 | 2.970 |
Why?
|
Humans | 444 | 2025 | 129650 | 2.910 |
Why?
|
Alveolitis, Extrinsic Allergic | 14 | 2023 | 98 | 2.540 |
Why?
|
Lung Neoplasms | 30 | 2023 | 2344 | 2.490 |
Why?
|
Middle Aged | 209 | 2025 | 31154 | 2.480 |
Why?
|
Smokers | 17 | 2024 | 138 | 2.410 |
Why?
|
Idiopathic Interstitial Pneumonias | 14 | 2019 | 49 | 2.290 |
Why?
|
Male | 254 | 2025 | 63681 | 2.200 |
Why?
|
Disease Progression | 51 | 2024 | 2635 | 2.160 |
Why?
|
Aged | 167 | 2025 | 22103 | 2.160 |
Why?
|
Diagnostic Imaging | 10 | 2024 | 334 | 2.070 |
Why?
|
Female | 250 | 2025 | 68776 | 2.030 |
Why?
|
Trinucleotide Repeat Expansion | 13 | 2024 | 26 | 1.940 |
Why?
|
Severity of Illness Index | 50 | 2024 | 2742 | 1.880 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 10 | 2021 | 212 | 1.840 |
Why?
|
Forced Expiratory Volume | 38 | 2024 | 510 | 1.820 |
Why?
|
Pattern Recognition, Automated | 4 | 2018 | 75 | 1.780 |
Why?
|
Biopsy | 27 | 2023 | 1097 | 1.760 |
Why?
|
Diagnosis, Differential | 41 | 2024 | 1434 | 1.700 |
Why?
|
Mucin-5B | 11 | 2025 | 217 | 1.600 |
Why?
|
Cohort Studies | 46 | 2025 | 5420 | 1.580 |
Why?
|
Triterpenes | 2 | 2023 | 20 | 1.430 |
Why?
|
Respiratory Function Tests | 30 | 2024 | 586 | 1.420 |
Why?
|
Adult | 110 | 2025 | 35576 | 1.370 |
Why?
|
Connective Tissue Diseases | 9 | 2019 | 82 | 1.320 |
Why?
|
Image Processing, Computer-Assisted | 11 | 2025 | 744 | 1.310 |
Why?
|
Quality of Life | 23 | 2024 | 2704 | 1.310 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 11 | 2017 | 99 | 1.310 |
Why?
|
Vital Capacity | 25 | 2024 | 291 | 1.310 |
Why?
|
Reproducibility of Results | 40 | 2024 | 3083 | 1.300 |
Why?
|
Bronchiectasis | 10 | 2024 | 108 | 1.290 |
Why?
|
Incidental Findings | 3 | 2021 | 79 | 1.260 |
Why?
|
Heterozygote | 6 | 2024 | 272 | 1.260 |
Why?
|
Phenotype | 24 | 2025 | 3076 | 1.240 |
Why?
|
Troponin I | 2 | 2024 | 75 | 1.220 |
Why?
|
Pulmonary Artery | 7 | 2024 | 1096 | 1.190 |
Why?
|
Magnetic Resonance Imaging | 18 | 2023 | 3408 | 1.140 |
Why?
|
Aged, 80 and over | 50 | 2021 | 7086 | 1.120 |
Why?
|
Early Detection of Cancer | 9 | 2023 | 370 | 1.100 |
Why?
|
Sarcoidosis | 3 | 2025 | 156 | 1.100 |
Why?
|
Heart Diseases | 3 | 2024 | 350 | 1.080 |
Why?
|
Occupational Diseases | 5 | 2015 | 138 | 1.050 |
Why?
|
Vision Disorders | 2 | 2020 | 135 | 1.000 |
Why?
|
Spirometry | 25 | 2024 | 257 | 0.990 |
Why?
|
Respiratory System Abnormalities | 2 | 2022 | 16 | 0.990 |
Why?
|
Sarcoidosis, Pulmonary | 5 | 2025 | 83 | 0.980 |
Why?
|
Young Adult | 31 | 2024 | 12426 | 0.980 |
Why?
|
NF-E2-Related Factor 2 | 3 | 2023 | 79 | 0.970 |
Why?
|
Antioxidants | 4 | 2014 | 559 | 0.960 |
Why?
|
Retrospective Studies | 54 | 2024 | 14518 | 0.960 |
Why?
|
Schizophrenia | 4 | 2022 | 431 | 0.950 |
Why?
|
Cerebellum | 3 | 2025 | 219 | 0.940 |
Why?
|
Common Variable Immunodeficiency | 3 | 2018 | 27 | 0.920 |
Why?
|
Sinusitis | 3 | 2023 | 210 | 0.910 |
Why?
|
Biomarkers | 16 | 2025 | 3973 | 0.900 |
Why?
|
Sensitivity and Specificity | 25 | 2021 | 1838 | 0.900 |
Why?
|
Positron-Emission Tomography | 5 | 2018 | 288 | 0.890 |
Why?
|
Lymph Nodes | 2 | 2019 | 472 | 0.880 |
Why?
|
Adolescent | 40 | 2024 | 20393 | 0.880 |
Why?
|
Paranasal Sinuses | 3 | 2023 | 76 | 0.870 |
Why?
|
Cystic Fibrosis | 8 | 2023 | 1053 | 0.870 |
Why?
|
Trinucleotide Repeats | 5 | 2023 | 25 | 0.870 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2024 | 99 | 0.860 |
Why?
|
Predictive Value of Tests | 13 | 2024 | 1952 | 0.860 |
Why?
|
Lung Injury | 2 | 2024 | 210 | 0.850 |
Why?
|
Respiratory-Gated Imaging Techniques | 3 | 2017 | 10 | 0.840 |
Why?
|
Prognosis | 24 | 2024 | 3794 | 0.820 |
Why?
|
Pulmonary Diffusing Capacity | 11 | 2024 | 74 | 0.810 |
Why?
|
Linoleic Acid | 1 | 2022 | 41 | 0.810 |
Why?
|
Ubiquinone | 3 | 2011 | 28 | 0.790 |
Why?
|
Cardiomyopathies | 4 | 2024 | 340 | 0.790 |
Why?
|
Neurons | 9 | 2018 | 1511 | 0.780 |
Why?
|
Anthracosis | 1 | 2022 | 10 | 0.770 |
Why?
|
Multiple Pulmonary Nodules | 2 | 2019 | 19 | 0.750 |
Why?
|
Double-Blind Method | 15 | 2024 | 1876 | 0.740 |
Why?
|
Homeostasis | 2 | 2016 | 611 | 0.740 |
Why?
|
Calpain | 4 | 2007 | 57 | 0.730 |
Why?
|
Algorithms | 11 | 2024 | 1622 | 0.710 |
Why?
|
Calcinosis | 1 | 2022 | 230 | 0.700 |
Why?
|
Neurodegenerative Diseases | 1 | 2022 | 113 | 0.690 |
Why?
|
Ataxia | 3 | 2023 | 42 | 0.680 |
Why?
|
Case-Control Studies | 23 | 2020 | 3381 | 0.670 |
Why?
|
Visual Acuity | 2 | 2020 | 322 | 0.670 |
Why?
|
Longitudinal Studies | 17 | 2023 | 2717 | 0.650 |
Why?
|
Dyspnea | 5 | 2023 | 242 | 0.640 |
Why?
|
Child | 37 | 2024 | 20883 | 0.640 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2013 | 385 | 0.630 |
Why?
|
Machine Learning | 9 | 2020 | 443 | 0.630 |
Why?
|
Genotype | 14 | 2025 | 1839 | 0.600 |
Why?
|
Prospective Studies | 28 | 2024 | 7133 | 0.590 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2021 | 443 | 0.590 |
Why?
|
Bronchitis, Chronic | 4 | 2023 | 19 | 0.580 |
Why?
|
Mass Screening | 8 | 2023 | 1149 | 0.570 |
Why?
|
Collagen Diseases | 3 | 2012 | 6 | 0.570 |
Why?
|
Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2017 | 17 | 0.570 |
Why?
|
Bronchiolitis | 5 | 2015 | 90 | 0.570 |
Why?
|
Risk Factors | 33 | 2024 | 9765 | 0.570 |
Why?
|
Thoracic Diseases | 2 | 2015 | 14 | 0.570 |
Why?
|
Follow-Up Studies | 21 | 2024 | 4897 | 0.550 |
Why?
|
Arthritis, Rheumatoid | 7 | 2024 | 1092 | 0.550 |
Why?
|
Occupational Exposure | 7 | 2020 | 299 | 0.540 |
Why?
|
Interdisciplinary Communication | 2 | 2016 | 186 | 0.540 |
Why?
|
Interferon-gamma | 2 | 2019 | 770 | 0.530 |
Why?
|
Patient Satisfaction | 1 | 2021 | 634 | 0.530 |
Why?
|
Observer Variation | 11 | 2021 | 315 | 0.530 |
Why?
|
Immunoassay | 3 | 2014 | 107 | 0.530 |
Why?
|
Bronchi | 3 | 2024 | 247 | 0.520 |
Why?
|
alpha7 Nicotinic Acetylcholine Receptor | 2 | 2014 | 104 | 0.520 |
Why?
|
Genetic Predisposition to Disease | 20 | 2020 | 2282 | 0.510 |
Why?
|
Mental Health Services | 1 | 2021 | 404 | 0.510 |
Why?
|
Echocardiography | 4 | 2017 | 629 | 0.500 |
Why?
|
Opsoclonus-Myoclonus Syndrome | 1 | 2015 | 1 | 0.500 |
Why?
|
Antigens, Surface | 2 | 2015 | 151 | 0.500 |
Why?
|
Genome-Wide Association Study | 12 | 2020 | 1333 | 0.490 |
Why?
|
Asthma | 7 | 2023 | 2230 | 0.490 |
Why?
|
Dendrites | 2 | 2018 | 100 | 0.490 |
Why?
|
Mitochondria | 4 | 2020 | 877 | 0.480 |
Why?
|
Telemedicine | 2 | 2021 | 788 | 0.480 |
Why?
|
Metabolic Diseases | 1 | 2016 | 104 | 0.480 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2016 | 61 | 0.470 |
Why?
|
Cells, Cultured | 11 | 2021 | 4083 | 0.470 |
Why?
|
Airway Remodeling | 7 | 2021 | 61 | 0.470 |
Why?
|
Tomography, Spiral Computed | 5 | 2013 | 27 | 0.460 |
Why?
|
NF-kappa B | 1 | 2018 | 653 | 0.460 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 759 | 0.460 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 115 | 0.460 |
Why?
|
Nerve Tissue Proteins | 6 | 2018 | 570 | 0.460 |
Why?
|
Parvalbumins | 1 | 2014 | 24 | 0.450 |
Why?
|
Polymorphism, Single Nucleotide | 10 | 2018 | 2073 | 0.450 |
Why?
|
Mutation | 9 | 2024 | 3717 | 0.450 |
Why?
|
Lymphatic Diseases | 1 | 2014 | 21 | 0.450 |
Why?
|
Olfaction Disorders | 3 | 2024 | 60 | 0.450 |
Why?
|
Radiographic Image Enhancement | 5 | 2020 | 54 | 0.440 |
Why?
|
Vascular Diseases | 2 | 2009 | 241 | 0.440 |
Why?
|
Mouth Mucosa | 2 | 2014 | 89 | 0.440 |
Why?
|
Regression Analysis | 11 | 2019 | 993 | 0.440 |
Why?
|
Mass Spectrometry | 7 | 2023 | 716 | 0.430 |
Why?
|
Nervous System Diseases | 3 | 2007 | 252 | 0.430 |
Why?
|
Autoantibodies | 7 | 2015 | 1466 | 0.430 |
Why?
|
Polymorphism, Genetic | 4 | 2017 | 640 | 0.420 |
Why?
|
Support Vector Machine | 1 | 2013 | 37 | 0.420 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2014 | 169 | 0.410 |
Why?
|
Spinocerebellar Degenerations | 2 | 2023 | 5 | 0.410 |
Why?
|
Sequence Analysis, RNA | 5 | 2018 | 429 | 0.410 |
Why?
|
Elasticity Imaging Techniques | 1 | 2013 | 47 | 0.410 |
Why?
|
Risk Assessment | 9 | 2025 | 3240 | 0.410 |
Why?
|
Cerebellar Ataxia | 2 | 2023 | 10 | 0.410 |
Why?
|
United States | 33 | 2024 | 13903 | 0.410 |
Why?
|
Receptor for Advanced Glycation End Products | 3 | 2022 | 31 | 0.400 |
Why?
|
Health Status | 6 | 2023 | 755 | 0.400 |
Why?
|
Angiography | 2 | 2013 | 195 | 0.400 |
Why?
|
Treatment Outcome | 18 | 2024 | 10230 | 0.400 |
Why?
|
Neuronal Plasticity | 3 | 2010 | 280 | 0.400 |
Why?
|
Radiation Dosage | 7 | 2024 | 153 | 0.390 |
Why?
|
Exhalation | 3 | 2018 | 39 | 0.390 |
Why?
|
Heart Failure | 2 | 2024 | 2150 | 0.380 |
Why?
|
Receptors, Nicotinic | 3 | 2015 | 329 | 0.380 |
Why?
|
Vena Cava, Superior | 1 | 2012 | 22 | 0.380 |
Why?
|
Exercise Test | 5 | 2024 | 613 | 0.380 |
Why?
|
Point Mutation | 4 | 2014 | 225 | 0.380 |
Why?
|
Asymptomatic Diseases | 1 | 2012 | 84 | 0.370 |
Why?
|
Osteosarcoma | 1 | 2012 | 72 | 0.370 |
Why?
|
Databases, Factual | 3 | 2024 | 1269 | 0.370 |
Why?
|
Pandemics | 5 | 2024 | 1488 | 0.370 |
Why?
|
Comorbidity | 9 | 2018 | 1547 | 0.370 |
Why?
|
Genetic Variation | 4 | 2019 | 937 | 0.360 |
Why?
|
Animals | 26 | 2025 | 35361 | 0.360 |
Why?
|
Rhinitis | 2 | 2023 | 152 | 0.360 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2022 | 312 | 0.360 |
Why?
|
Glucose | 1 | 2016 | 1003 | 0.360 |
Why?
|
Echocardiography, Doppler | 1 | 2011 | 108 | 0.360 |
Why?
|
Imaging, Three-Dimensional | 5 | 2021 | 531 | 0.350 |
Why?
|
Respiratory Tract Diseases | 3 | 2018 | 148 | 0.350 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2011 | 126 | 0.350 |
Why?
|
Doxorubicin | 1 | 2012 | 325 | 0.350 |
Why?
|
Pulmonary Embolism | 2 | 2012 | 211 | 0.340 |
Why?
|
Heart Transplantation | 1 | 2017 | 721 | 0.340 |
Why?
|
Chronic Disease | 9 | 2024 | 1720 | 0.340 |
Why?
|
Cysts | 3 | 2023 | 109 | 0.340 |
Why?
|
Myocardial Contraction | 1 | 2011 | 335 | 0.340 |
Why?
|
Dysarthria | 1 | 2010 | 9 | 0.340 |
Why?
|
Survival Analysis | 7 | 2020 | 1274 | 0.340 |
Why?
|
Child, Preschool | 13 | 2024 | 10517 | 0.330 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2020 | 254 | 0.330 |
Why?
|
Bone Neoplasms | 1 | 2012 | 231 | 0.330 |
Why?
|
Encephalitis | 2 | 2008 | 133 | 0.330 |
Why?
|
Presynaptic Terminals | 1 | 2010 | 83 | 0.330 |
Why?
|
Stroke Volume | 2 | 2017 | 592 | 0.330 |
Why?
|
Pulmonary Atelectasis | 3 | 2018 | 13 | 0.330 |
Why?
|
Multivariate Analysis | 10 | 2019 | 1502 | 0.320 |
Why?
|
Mice, Inbred C57BL | 7 | 2025 | 5440 | 0.320 |
Why?
|
Hyperostosis, Diffuse Idiopathic Skeletal | 2 | 2019 | 4 | 0.320 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2014 | 821 | 0.320 |
Why?
|
Lung Volume Measurements | 4 | 2024 | 45 | 0.320 |
Why?
|
Gadolinium | 4 | 2020 | 78 | 0.310 |
Why?
|
Cross-Sectional Studies | 13 | 2024 | 5066 | 0.310 |
Why?
|
Tomography, Emission-Computed | 2 | 2006 | 66 | 0.310 |
Why?
|
Artificial Intelligence | 3 | 2025 | 246 | 0.300 |
Why?
|
ROC Curve | 5 | 2019 | 503 | 0.300 |
Why?
|
Surveys and Questionnaires | 11 | 2021 | 5406 | 0.300 |
Why?
|
Autoimmune Diseases of the Nervous System | 1 | 2008 | 24 | 0.300 |
Why?
|
Birt-Hogg-Dube Syndrome | 4 | 2023 | 7 | 0.300 |
Why?
|
Fibroblasts | 6 | 2022 | 948 | 0.300 |
Why?
|
Bronchioles | 2 | 2019 | 23 | 0.300 |
Why?
|
Feasibility Studies | 5 | 2018 | 868 | 0.300 |
Why?
|
Radiology | 2 | 2014 | 161 | 0.290 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 1501 | 0.290 |
Why?
|
Blood Platelets | 3 | 2018 | 380 | 0.290 |
Why?
|
Linear Models | 8 | 2018 | 819 | 0.290 |
Why?
|
Histiocytosis, Langerhans-Cell | 4 | 2023 | 37 | 0.290 |
Why?
|
Analysis of Variance | 5 | 2014 | 1288 | 0.290 |
Why?
|
Receptors, AMPA | 2 | 2025 | 141 | 0.290 |
Why?
|
Clinical Decision-Making | 2 | 2021 | 303 | 0.290 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 2012 | 0.280 |
Why?
|
Sex Factors | 5 | 2018 | 1968 | 0.280 |
Why?
|
Cerebral Cortex | 5 | 2018 | 437 | 0.280 |
Why?
|
Nitrogen Dioxide | 1 | 2007 | 32 | 0.280 |
Why?
|
Siblings | 1 | 2008 | 215 | 0.280 |
Why?
|
Schizophrenic Psychology | 3 | 2022 | 94 | 0.270 |
Why?
|
Pseudomonas Infections | 1 | 2009 | 221 | 0.270 |
Why?
|
Respiration | 5 | 2023 | 191 | 0.270 |
Why?
|
Body Mass Index | 7 | 2018 | 2273 | 0.270 |
Why?
|
Mice | 12 | 2025 | 16937 | 0.270 |
Why?
|
alpha 1-Antitrypsin Deficiency | 2 | 2023 | 67 | 0.270 |
Why?
|
Acute Disease | 6 | 2021 | 980 | 0.260 |
Why?
|
Receptors, Metabotropic Glutamate | 1 | 2007 | 41 | 0.260 |
Why?
|
Consensus | 2 | 2023 | 616 | 0.260 |
Why?
|
Neurologic Examination | 3 | 2012 | 115 | 0.260 |
Why?
|
Total Lung Capacity | 7 | 2020 | 33 | 0.260 |
Why?
|
Bronchography | 3 | 2013 | 10 | 0.260 |
Why?
|
Autoimmune Diseases | 2 | 2024 | 426 | 0.260 |
Why?
|
Alleles | 6 | 2019 | 845 | 0.260 |
Why?
|
Synapses | 2 | 2009 | 400 | 0.260 |
Why?
|
Lymphangioleiomyomatosis | 3 | 2023 | 34 | 0.260 |
Why?
|
Chromatography, Liquid | 4 | 2018 | 423 | 0.260 |
Why?
|
Protein Subunits | 3 | 2021 | 235 | 0.250 |
Why?
|
Prevalence | 10 | 2024 | 2564 | 0.250 |
Why?
|
Blotting, Western | 5 | 2019 | 1205 | 0.250 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 1052 | 0.250 |
Why?
|
Early Diagnosis | 5 | 2021 | 234 | 0.240 |
Why?
|
Airway Obstruction | 2 | 2019 | 152 | 0.240 |
Why?
|
Walking | 3 | 2022 | 501 | 0.240 |
Why?
|
Mycobacterium Infections | 1 | 2005 | 62 | 0.240 |
Why?
|
Pregnancy Complications | 1 | 2010 | 493 | 0.240 |
Why?
|
Solitary Pulmonary Nodule | 3 | 2016 | 20 | 0.240 |
Why?
|
Age Factors | 5 | 2015 | 3144 | 0.240 |
Why?
|
Genetic Association Studies | 2 | 2019 | 360 | 0.240 |
Why?
|
beta Catenin | 1 | 2007 | 223 | 0.240 |
Why?
|
Bronchial Arteries | 1 | 2024 | 12 | 0.230 |
Why?
|
Heart Defects, Congenital | 1 | 2012 | 758 | 0.230 |
Why?
|
Recombinant Proteins | 3 | 2019 | 1304 | 0.230 |
Why?
|
Radiopharmaceuticals | 2 | 2016 | 168 | 0.230 |
Why?
|
Logistic Models | 10 | 2018 | 1988 | 0.230 |
Why?
|
Proportional Hazards Models | 6 | 2024 | 1201 | 0.230 |
Why?
|
Hypoxia | 1 | 2012 | 1084 | 0.230 |
Why?
|
Protein Isoforms | 3 | 2019 | 391 | 0.230 |
Why?
|
Hippocampus | 3 | 2009 | 874 | 0.230 |
Why?
|
Diaphragm | 1 | 2024 | 43 | 0.230 |
Why?
|
Patient Positioning | 1 | 2024 | 52 | 0.230 |
Why?
|
Patient Care Team | 2 | 2016 | 605 | 0.220 |
Why?
|
Dopamine | 2 | 2006 | 289 | 0.220 |
Why?
|
Mucus | 1 | 2025 | 77 | 0.220 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 274 | 0.220 |
Why?
|
Purkinje Cells | 1 | 2025 | 71 | 0.220 |
Why?
|
Blood Glucose | 1 | 2014 | 2097 | 0.220 |
Why?
|
Embryo, Mammalian | 2 | 2015 | 226 | 0.220 |
Why?
|
Time Factors | 10 | 2024 | 6556 | 0.220 |
Why?
|
Troponin T | 1 | 2024 | 57 | 0.220 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2005 | 287 | 0.220 |
Why?
|
Introns | 2 | 2023 | 251 | 0.220 |
Why?
|
Cluster Analysis | 4 | 2019 | 482 | 0.220 |
Why?
|
Tropanes | 1 | 2003 | 5 | 0.210 |
Why?
|
Organotechnetium Compounds | 1 | 2003 | 10 | 0.210 |
Why?
|
Survival Rate | 6 | 2018 | 1877 | 0.210 |
Why?
|
Molecular Epidemiology | 2 | 2022 | 63 | 0.210 |
Why?
|
Patient Advocacy | 1 | 2024 | 73 | 0.210 |
Why?
|
International Cooperation | 4 | 2017 | 174 | 0.210 |
Why?
|
Blood Proteins | 1 | 2025 | 242 | 0.210 |
Why?
|
Incidence | 9 | 2023 | 2644 | 0.210 |
Why?
|
Contrast Media | 3 | 2020 | 394 | 0.210 |
Why?
|
Motivation | 3 | 2022 | 546 | 0.210 |
Why?
|
Disease Models, Animal | 3 | 2025 | 4063 | 0.210 |
Why?
|
Rats | 6 | 2015 | 5500 | 0.210 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 77 | 0.210 |
Why?
|
Linoleic Acids | 1 | 2022 | 7 | 0.210 |
Why?
|
Mitochondrial Proteins | 2 | 2023 | 248 | 0.210 |
Why?
|
Models, Biological | 4 | 2017 | 1722 | 0.200 |
Why?
|
Corpus Striatum | 2 | 2006 | 159 | 0.200 |
Why?
|
Membrane Glycoproteins | 2 | 2015 | 474 | 0.200 |
Why?
|
Age of Onset | 6 | 2019 | 496 | 0.200 |
Why?
|
Carcinogens, Environmental | 1 | 2002 | 7 | 0.200 |
Why?
|
Smell | 1 | 2023 | 137 | 0.200 |
Why?
|
Perioperative Care | 1 | 2024 | 152 | 0.200 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 1004 | 0.200 |
Why?
|
Pneumoconiosis | 1 | 2002 | 19 | 0.200 |
Why?
|
Promoter Regions, Genetic | 5 | 2019 | 1207 | 0.200 |
Why?
|
Asbestos | 1 | 2002 | 28 | 0.200 |
Why?
|
Ventricular Function | 2 | 2017 | 61 | 0.200 |
Why?
|
Delphi Technique | 1 | 2023 | 225 | 0.200 |
Why?
|
Antibodies | 2 | 2019 | 398 | 0.200 |
Why?
|
Sjogren's Syndrome | 3 | 2019 | 48 | 0.200 |
Why?
|
Chi-Square Distribution | 5 | 2013 | 516 | 0.200 |
Why?
|
Guanine | 3 | 2022 | 76 | 0.190 |
Why?
|
Diabetes Mellitus | 3 | 2016 | 1001 | 0.190 |
Why?
|
Membrane Transport Proteins | 1 | 2003 | 149 | 0.190 |
Why?
|
Bleomycin | 3 | 2021 | 244 | 0.190 |
Why?
|
Mesothelioma | 1 | 2002 | 38 | 0.190 |
Why?
|
Aftercare | 1 | 2024 | 205 | 0.190 |
Why?
|
Bronchial Diseases | 2 | 2012 | 38 | 0.190 |
Why?
|
Genetic Therapy | 2 | 2021 | 292 | 0.190 |
Why?
|
Chromosome Deletion | 2 | 2015 | 104 | 0.190 |
Why?
|
Environmental Exposure | 4 | 2020 | 462 | 0.190 |
Why?
|
Tomography Scanners, X-Ray Computed | 2 | 2017 | 19 | 0.190 |
Why?
|
Peptide Hydrolases | 1 | 2002 | 107 | 0.190 |
Why?
|
Hypertension, Pulmonary | 5 | 2021 | 1894 | 0.190 |
Why?
|
Cyclophosphamide | 3 | 2011 | 232 | 0.190 |
Why?
|
Fibrosis | 7 | 2022 | 520 | 0.180 |
Why?
|
Societies, Medical | 8 | 2021 | 751 | 0.180 |
Why?
|
Carbon Monoxide | 3 | 2019 | 68 | 0.180 |
Why?
|
Symptom Flare Up | 1 | 2021 | 38 | 0.180 |
Why?
|
Retinoids | 1 | 2021 | 33 | 0.180 |
Why?
|
Respiration Disorders | 1 | 2021 | 72 | 0.180 |
Why?
|
Spinal Fusion | 1 | 2024 | 230 | 0.180 |
Why?
|
Pulmonary Surfactant-Associated Protein C | 1 | 2021 | 44 | 0.180 |
Why?
|
Statistics as Topic | 4 | 2012 | 307 | 0.180 |
Why?
|
Protein C | 1 | 2021 | 47 | 0.180 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2024 | 226 | 0.180 |
Why?
|
Scleroderma, Systemic | 3 | 2019 | 114 | 0.180 |
Why?
|
RNA Stability | 1 | 2021 | 102 | 0.180 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 89 | 0.180 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 891 | 0.180 |
Why?
|
DNA | 2 | 2018 | 1400 | 0.170 |
Why?
|
Genetic Testing | 2 | 2008 | 428 | 0.170 |
Why?
|
Bacteriophages | 1 | 2022 | 93 | 0.170 |
Why?
|
RNA, Messenger | 5 | 2021 | 2708 | 0.170 |
Why?
|
Patient Care Management | 1 | 2021 | 56 | 0.170 |
Why?
|
Mycobacterium abscessus | 1 | 2022 | 107 | 0.170 |
Why?
|
Brain | 3 | 2020 | 2679 | 0.170 |
Why?
|
Pulmonary Medicine | 3 | 2015 | 79 | 0.170 |
Why?
|
Adenine | 3 | 2022 | 256 | 0.170 |
Why?
|
Intermediate Filaments | 1 | 2020 | 27 | 0.170 |
Why?
|
Cognitive Remediation | 1 | 2020 | 1 | 0.170 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2022 | 529 | 0.170 |
Why?
|
Mice, Knockout | 2 | 2025 | 2871 | 0.170 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 198 | 0.170 |
Why?
|
Rare Diseases | 2 | 2018 | 100 | 0.170 |
Why?
|
Health Resources | 1 | 2021 | 114 | 0.170 |
Why?
|
Neurofilament Proteins | 1 | 2020 | 43 | 0.170 |
Why?
|
Teratoma | 3 | 2010 | 105 | 0.170 |
Why?
|
Pneumonia | 5 | 2013 | 616 | 0.160 |
Why?
|
Vasoconstriction | 1 | 2021 | 199 | 0.160 |
Why?
|
Pilot Projects | 2 | 2022 | 1587 | 0.160 |
Why?
|
Hyperostosis | 1 | 2019 | 5 | 0.160 |
Why?
|
Desmoplakins | 1 | 2019 | 19 | 0.160 |
Why?
|
Sensorimotor Cortex | 1 | 2019 | 5 | 0.160 |
Why?
|
Afferent Pathways | 1 | 2019 | 45 | 0.160 |
Why?
|
Genetic Markers | 3 | 2021 | 338 | 0.160 |
Why?
|
Cigarette Smoking | 2 | 2020 | 91 | 0.160 |
Why?
|
DiGeorge Syndrome | 2 | 2012 | 29 | 0.160 |
Why?
|
Proprioception | 1 | 2019 | 26 | 0.160 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2021 | 259 | 0.160 |
Why?
|
Communication | 2 | 2024 | 846 | 0.160 |
Why?
|
Ambulatory Care Facilities | 1 | 2021 | 228 | 0.160 |
Why?
|
Racemases and Epimerases | 1 | 2018 | 11 | 0.160 |
Why?
|
Models, Theoretical | 2 | 2020 | 547 | 0.150 |
Why?
|
Minimal Clinically Important Difference | 1 | 2018 | 13 | 0.150 |
Why?
|
Sex Distribution | 5 | 2016 | 359 | 0.150 |
Why?
|
Iron Regulatory Protein 2 | 2 | 2015 | 6 | 0.150 |
Why?
|
Proteomics | 3 | 2025 | 1062 | 0.150 |
Why?
|
Parkinson Disease | 2 | 2006 | 463 | 0.150 |
Why?
|
Oral Hygiene | 1 | 2018 | 17 | 0.150 |
Why?
|
Scleroderma, Limited | 2 | 2008 | 5 | 0.150 |
Why?
|
Cause of Death | 2 | 2018 | 393 | 0.150 |
Why?
|
Genetic Loci | 3 | 2016 | 275 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 1368 | 0.150 |
Why?
|
Indoles | 2 | 2019 | 387 | 0.150 |
Why?
|
Psychometrics | 1 | 2022 | 691 | 0.150 |
Why?
|
Membrane Proteins | 2 | 2015 | 1119 | 0.150 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 253 | 0.150 |
Why?
|
Carrier Proteins | 3 | 2015 | 743 | 0.150 |
Why?
|
Apolipoprotein A-I | 1 | 2018 | 28 | 0.150 |
Why?
|
September 11 Terrorist Attacks | 1 | 2018 | 31 | 0.150 |
Why?
|
Air Pollutants, Occupational | 1 | 2018 | 32 | 0.150 |
Why?
|
Self-Help Devices | 1 | 2018 | 20 | 0.150 |
Why?
|
Societies | 1 | 2017 | 38 | 0.140 |
Why?
|
Traction | 3 | 2023 | 19 | 0.140 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 390 | 0.140 |
Why?
|
Fatigue | 1 | 2019 | 318 | 0.140 |
Why?
|
Vascular Calcification | 1 | 2019 | 107 | 0.140 |
Why?
|
Respiratory System | 2 | 2016 | 154 | 0.140 |
Why?
|
Pleura | 2 | 2015 | 22 | 0.140 |
Why?
|
Genomic Instability | 1 | 2017 | 48 | 0.140 |
Why?
|
Cryptogenic Organizing Pneumonia | 2 | 2009 | 19 | 0.140 |
Why?
|
Spine | 1 | 2019 | 158 | 0.140 |
Why?
|
Motion | 1 | 2017 | 98 | 0.140 |
Why?
|
Cardiac Volume | 1 | 2017 | 12 | 0.140 |
Why?
|
Premature Birth | 2 | 2012 | 314 | 0.140 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2022 | 352 | 0.140 |
Why?
|
Principal Component Analysis | 1 | 2017 | 189 | 0.140 |
Why?
|
Parenchymal Tissue | 1 | 2016 | 6 | 0.140 |
Why?
|
Complement C3 | 1 | 2018 | 203 | 0.130 |
Why?
|
Bronchiolitis Obliterans | 2 | 2009 | 68 | 0.130 |
Why?
|
Evidence-Based Medicine | 3 | 2021 | 718 | 0.130 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 335 | 0.130 |
Why?
|
Bayes Theorem | 2 | 2022 | 375 | 0.130 |
Why?
|
Computed Tomography Angiography | 1 | 2018 | 115 | 0.130 |
Why?
|
Nursing Homes | 1 | 2018 | 159 | 0.130 |
Why?
|
Calibration | 1 | 2017 | 140 | 0.130 |
Why?
|
Program Evaluation | 1 | 2021 | 875 | 0.130 |
Why?
|
Creatine | 1 | 2016 | 58 | 0.130 |
Why?
|
Mucociliary Clearance | 1 | 2016 | 42 | 0.130 |
Why?
|
Arthritis, Experimental | 1 | 2018 | 128 | 0.130 |
Why?
|
Software Validation | 1 | 2016 | 9 | 0.130 |
Why?
|
Pulmonary Alveoli | 2 | 2016 | 400 | 0.130 |
Why?
|
HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.130 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 284 | 0.130 |
Why?
|
Respiratory Insufficiency | 2 | 2017 | 313 | 0.130 |
Why?
|
Republic of Korea | 3 | 2023 | 29 | 0.130 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 46 | 0.130 |
Why?
|
Tracheal Diseases | 1 | 2016 | 16 | 0.130 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2015 | 28 | 0.130 |
Why?
|
Pleural Diseases | 1 | 2015 | 18 | 0.130 |
Why?
|
Mitochondrial Diseases | 1 | 2016 | 90 | 0.130 |
Why?
|
Reference Values | 3 | 2013 | 793 | 0.120 |
Why?
|
HLA-DRB1 Chains | 1 | 2016 | 108 | 0.120 |
Why?
|
Referral and Consultation | 1 | 2021 | 732 | 0.120 |
Why?
|
Genomics | 1 | 2021 | 716 | 0.120 |
Why?
|
Guanylate Kinases | 1 | 2015 | 13 | 0.120 |
Why?
|
ELAV Proteins | 1 | 2015 | 14 | 0.120 |
Why?
|
Neoplasm Staging | 3 | 2011 | 1295 | 0.120 |
Why?
|
Collagen | 1 | 2018 | 434 | 0.120 |
Why?
|
Disks Large Homolog 4 Protein | 1 | 2015 | 17 | 0.120 |
Why?
|
Oxidative Phosphorylation | 1 | 2016 | 187 | 0.120 |
Why?
|
Azathioprine | 1 | 2015 | 50 | 0.120 |
Why?
|
Sildenafil Citrate | 1 | 2015 | 59 | 0.120 |
Why?
|
Transcription Elongation, Genetic | 1 | 2015 | 22 | 0.120 |
Why?
|
Military Personnel | 1 | 2022 | 515 | 0.120 |
Why?
|
Gene Expression Regulation | 4 | 2018 | 2548 | 0.120 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 341 | 0.120 |
Why?
|
Cell Line | 4 | 2016 | 2781 | 0.120 |
Why?
|
Electrocardiography | 3 | 2017 | 608 | 0.120 |
Why?
|
Occupational Health | 1 | 2018 | 192 | 0.120 |
Why?
|
Interferon-beta | 2 | 2008 | 89 | 0.120 |
Why?
|
Coronavirus Infections | 1 | 2020 | 335 | 0.120 |
Why?
|
Multicenter Studies as Topic | 2 | 2014 | 286 | 0.120 |
Why?
|
Galactosylceramidase | 1 | 2015 | 3 | 0.120 |
Why?
|
Inflammation Mediators | 1 | 2018 | 505 | 0.120 |
Why?
|
Protein Biosynthesis | 1 | 2017 | 406 | 0.120 |
Why?
|
Patient Selection | 2 | 2020 | 663 | 0.120 |
Why?
|
Cryopreservation | 1 | 2016 | 97 | 0.120 |
Why?
|
Mycobacterium avium Complex | 1 | 2016 | 88 | 0.120 |
Why?
|
Glucose Tolerance Test | 1 | 2016 | 356 | 0.120 |
Why?
|
Cognitive Dysfunction | 1 | 2020 | 346 | 0.120 |
Why?
|
Receptors, GABA-A | 2 | 2014 | 127 | 0.120 |
Why?
|
Epithelial Cells | 1 | 2021 | 1065 | 0.120 |
Why?
|
Axonemal Dyneins | 1 | 2014 | 9 | 0.120 |
Why?
|
Comparative Effectiveness Research | 1 | 2016 | 149 | 0.120 |
Why?
|
Adenocarcinoma | 2 | 2012 | 898 | 0.120 |
Why?
|
Brain Stem | 1 | 2015 | 98 | 0.120 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 170 | 0.120 |
Why?
|
Pyridones | 2 | 2023 | 159 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 857 | 0.110 |
Why?
|
Prednisone | 1 | 2015 | 233 | 0.110 |
Why?
|
Gene Silencing | 1 | 2015 | 190 | 0.110 |
Why?
|
Transcriptome | 2 | 2018 | 887 | 0.110 |
Why?
|
Physicians | 2 | 2022 | 865 | 0.110 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2019 | 759 | 0.110 |
Why?
|
Inhibitory Postsynaptic Potentials | 1 | 2014 | 40 | 0.110 |
Why?
|
Tyrosine | 2 | 2005 | 223 | 0.110 |
Why?
|
Spinal Fractures | 1 | 2015 | 81 | 0.110 |
Why?
|
Catechol O-Methyltransferase | 2 | 2004 | 18 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2007 | 359 | 0.110 |
Why?
|
Birth Weight | 2 | 2024 | 505 | 0.110 |
Why?
|
Myocardium | 1 | 2019 | 980 | 0.110 |
Why?
|
Mass Chest X-Ray | 2 | 2010 | 4 | 0.110 |
Why?
|
Glutamate Decarboxylase | 1 | 2014 | 166 | 0.110 |
Why?
|
Age Distribution | 3 | 2016 | 372 | 0.110 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 2005 | 100 | 0.110 |
Why?
|
Infant | 6 | 2024 | 9024 | 0.110 |
Why?
|
Contrast Sensitivity | 1 | 2013 | 13 | 0.110 |
Why?
|
Membrane Potentials | 1 | 2014 | 293 | 0.110 |
Why?
|
Multidetector Computed Tomography | 3 | 2019 | 33 | 0.110 |
Why?
|
Anisotropy | 1 | 2013 | 74 | 0.110 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2013 | 26 | 0.100 |
Why?
|
Heart Ventricles | 2 | 2017 | 781 | 0.100 |
Why?
|
Erythrocytes | 1 | 2018 | 672 | 0.100 |
Why?
|
Immunosuppressive Agents | 3 | 2015 | 853 | 0.100 |
Why?
|
Qc-SNARE Proteins | 1 | 2012 | 7 | 0.100 |
Why?
|
Qb-SNARE Proteins | 1 | 2012 | 6 | 0.100 |
Why?
|
Research Design | 3 | 2022 | 1044 | 0.100 |
Why?
|
Protons | 1 | 2013 | 80 | 0.100 |
Why?
|
Liver | 2 | 2020 | 1839 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1565 | 0.100 |
Why?
|
Elastic Modulus | 1 | 2013 | 123 | 0.100 |
Why?
|
Inflammation | 4 | 2018 | 2736 | 0.100 |
Why?
|
Respiratory Mechanics | 1 | 2013 | 64 | 0.100 |
Why?
|
Iopamidol | 1 | 2012 | 16 | 0.100 |
Why?
|
Carcinoma, Bronchogenic | 2 | 2002 | 19 | 0.100 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2024 | 161 | 0.100 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 679 | 0.100 |
Why?
|
Radiologists | 2 | 2024 | 41 | 0.100 |
Why?
|
Blood Cells | 1 | 2012 | 39 | 0.100 |
Why?
|
Fasting | 1 | 2014 | 267 | 0.100 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2014 | 200 | 0.100 |
Why?
|
Dextrocardia | 1 | 2012 | 3 | 0.100 |
Why?
|
Ventricular Dysfunction | 1 | 2012 | 15 | 0.100 |
Why?
|
Osteoporosis | 1 | 2015 | 232 | 0.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 430 | 0.100 |
Why?
|
Mental Disorders | 1 | 2020 | 1030 | 0.090 |
Why?
|
Animals, Newborn | 1 | 2014 | 835 | 0.090 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 2 | 2008 | 12 | 0.090 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 123 | 0.090 |
Why?
|
Blood Vessels | 1 | 2013 | 187 | 0.090 |
Why?
|
Tomography, Optical Coherence | 1 | 2013 | 187 | 0.090 |
Why?
|
Cilia | 1 | 2013 | 179 | 0.090 |
Why?
|
Bronchoscopy | 3 | 2021 | 216 | 0.090 |
Why?
|
Diastole | 1 | 2011 | 148 | 0.090 |
Why?
|
Sarcoma, Kaposi | 1 | 2012 | 76 | 0.090 |
Why?
|
Stress, Mechanical | 1 | 2013 | 467 | 0.090 |
Why?
|
Sodium Chloride | 1 | 2012 | 138 | 0.090 |
Why?
|
Bone Density | 1 | 2015 | 471 | 0.090 |
Why?
|
Heart Atria | 1 | 2012 | 128 | 0.090 |
Why?
|
Methotrexate | 1 | 2012 | 249 | 0.090 |
Why?
|
Mice, Transgenic | 2 | 2014 | 2119 | 0.090 |
Why?
|
Miniature Postsynaptic Potentials | 1 | 2010 | 9 | 0.090 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 72 | 0.090 |
Why?
|
Apgar Score | 1 | 2010 | 16 | 0.090 |
Why?
|
Term Birth | 1 | 2010 | 20 | 0.090 |
Why?
|
Inflammasomes | 1 | 2012 | 126 | 0.090 |
Why?
|
Peptides, Cyclic | 1 | 2012 | 256 | 0.090 |
Why?
|
Cisplatin | 1 | 2012 | 300 | 0.090 |
Why?
|
Hemoptysis | 1 | 2010 | 35 | 0.080 |
Why?
|
Speech Disorders | 1 | 2010 | 34 | 0.080 |
Why?
|
Live Birth | 1 | 2010 | 57 | 0.080 |
Why?
|
Leg | 1 | 2012 | 238 | 0.080 |
Why?
|
Registries | 2 | 2017 | 1896 | 0.080 |
Why?
|
Scleroderma, Localized | 1 | 2009 | 8 | 0.080 |
Why?
|
Polymyositis | 1 | 2009 | 15 | 0.080 |
Why?
|
Aminophenols | 2 | 2022 | 144 | 0.080 |
Why?
|
Autoimmunity | 2 | 2015 | 862 | 0.080 |
Why?
|
Excitatory Postsynaptic Potentials | 1 | 2010 | 120 | 0.080 |
Why?
|
Aorta | 1 | 2012 | 411 | 0.080 |
Why?
|
Acute Lung Injury | 1 | 2013 | 279 | 0.080 |
Why?
|
Hepatectomy | 1 | 2011 | 212 | 0.080 |
Why?
|
Walk Test | 2 | 2021 | 70 | 0.080 |
Why?
|
Chromosomes, Human, Pair 22 | 2 | 2006 | 41 | 0.080 |
Why?
|
Patch-Clamp Techniques | 1 | 2010 | 279 | 0.080 |
Why?
|
X-Ray Microtomography | 2 | 2021 | 84 | 0.080 |
Why?
|
Abortion, Spontaneous | 1 | 2010 | 100 | 0.080 |
Why?
|
Gene Expression Profiling | 4 | 2018 | 1706 | 0.080 |
Why?
|
Salivary Glands, Minor | 1 | 2009 | 9 | 0.080 |
Why?
|
Reactive Oxygen Species | 1 | 2012 | 596 | 0.080 |
Why?
|
Limbic Encephalitis | 1 | 2009 | 4 | 0.080 |
Why?
|
Survivors | 1 | 2013 | 464 | 0.080 |
Why?
|
alpha-Synuclein | 2 | 2006 | 32 | 0.080 |
Why?
|
Antibodies, Antinuclear | 1 | 2009 | 66 | 0.080 |
Why?
|
Amino Acyl-tRNA Synthetases | 1 | 2009 | 30 | 0.080 |
Why?
|
Up-Regulation | 1 | 2012 | 840 | 0.080 |
Why?
|
Speech | 1 | 2010 | 74 | 0.080 |
Why?
|
Delivery, Obstetric | 1 | 2010 | 137 | 0.080 |
Why?
|
Iron Chelating Agents | 1 | 2009 | 18 | 0.080 |
Why?
|
Exercise Tolerance | 3 | 2016 | 273 | 0.080 |
Why?
|
Autoantigens | 2 | 2009 | 417 | 0.080 |
Why?
|
Spondylitis, Ankylosing | 1 | 2009 | 46 | 0.080 |
Why?
|
Axons | 1 | 2010 | 191 | 0.080 |
Why?
|
Neurocognitive Disorders | 1 | 2008 | 26 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2016 | 129 | 0.080 |
Why?
|
Radiography | 4 | 2004 | 798 | 0.080 |
Why?
|
Scleroderma, Diffuse | 1 | 2008 | 4 | 0.080 |
Why?
|
DNA, Mitochondrial | 1 | 2010 | 191 | 0.080 |
Why?
|
Tandem Repeat Sequences | 1 | 2008 | 18 | 0.080 |
Why?
|
Patient Reported Outcome Measures | 2 | 2022 | 373 | 0.080 |
Why?
|
Arrhythmias, Cardiac | 1 | 2011 | 317 | 0.080 |
Why?
|
Tobacco Use Disorder | 1 | 2011 | 237 | 0.080 |
Why?
|
Europe | 3 | 2015 | 364 | 0.070 |
Why?
|
Calcium Signaling | 1 | 2010 | 250 | 0.070 |
Why?
|
Hereditary Central Nervous System Demyelinating Diseases | 1 | 2008 | 2 | 0.070 |
Why?
|
Eukaryotic Initiation Factor-2B | 1 | 2008 | 6 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 1206 | 0.070 |
Why?
|
Organophosphorus Compounds | 1 | 2009 | 79 | 0.070 |
Why?
|
Hospitalization | 2 | 2014 | 2070 | 0.070 |
Why?
|
Transfection | 3 | 2009 | 911 | 0.070 |
Why?
|
Erythropoietin | 1 | 2009 | 86 | 0.070 |
Why?
|
Insulin | 3 | 2014 | 2326 | 0.070 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2011 | 381 | 0.070 |
Why?
|
Infant, Newborn | 3 | 2024 | 5762 | 0.070 |
Why?
|
Genetic Heterogeneity | 1 | 2008 | 58 | 0.070 |
Why?
|
Neurotoxins | 1 | 2007 | 28 | 0.070 |
Why?
|
Cytoprotection | 1 | 2007 | 56 | 0.070 |
Why?
|
Catheter Ablation | 1 | 2011 | 335 | 0.070 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2024 | 123 | 0.070 |
Why?
|
Community Medicine | 1 | 2007 | 5 | 0.070 |
Why?
|
Sulfonamides | 1 | 2011 | 496 | 0.070 |
Why?
|
Area Under Curve | 2 | 2018 | 304 | 0.070 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 485 | 0.070 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2009 | 209 | 0.070 |
Why?
|
Phosphorylation | 2 | 2016 | 1713 | 0.070 |
Why?
|
DNA Methylation | 1 | 2012 | 607 | 0.070 |
Why?
|
Japan | 2 | 2021 | 98 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 247 | 0.070 |
Why?
|
Pericardium | 1 | 2007 | 54 | 0.070 |
Why?
|
Activities of Daily Living | 1 | 2010 | 384 | 0.070 |
Why?
|
Muscle, Skeletal | 1 | 2016 | 1614 | 0.070 |
Why?
|
Brain Diseases | 1 | 2008 | 137 | 0.070 |
Why?
|
Cyclin-Dependent Kinase 5 | 1 | 2006 | 3 | 0.070 |
Why?
|
Ovarian Neoplasms | 2 | 2010 | 490 | 0.070 |
Why?
|
Sodium-Calcium Exchanger | 1 | 2006 | 16 | 0.070 |
Why?
|
Neuroprotective Agents | 1 | 2007 | 122 | 0.070 |
Why?
|
Inositol 1,4,5-Trisphosphate Receptors | 1 | 2006 | 31 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2007 | 422 | 0.060 |
Why?
|
Epitopes | 1 | 2008 | 470 | 0.060 |
Why?
|
Pneumonectomy | 2 | 2023 | 151 | 0.060 |
Why?
|
Internationality | 2 | 2017 | 149 | 0.060 |
Why?
|
United Kingdom | 2 | 2019 | 257 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 2061 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 626 | 0.060 |
Why?
|
Cytosol | 1 | 2006 | 218 | 0.060 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 181 | 0.060 |
Why?
|
Administration, Inhalation | 1 | 2007 | 666 | 0.060 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 110 | 0.060 |
Why?
|
Organ Size | 2 | 2016 | 447 | 0.060 |
Why?
|
HEK293 Cells | 2 | 2018 | 697 | 0.060 |
Why?
|
MicroRNAs | 1 | 2012 | 678 | 0.060 |
Why?
|
Amino Acid Sequence | 2 | 2020 | 2058 | 0.060 |
Why?
|
Conotoxins | 1 | 2005 | 14 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 487 | 0.060 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 1 | 2025 | 35 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 827 | 0.060 |
Why?
|
Isotopes | 2 | 2015 | 32 | 0.060 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 2019 | 330 | 0.060 |
Why?
|
Cognition | 2 | 2021 | 1123 | 0.060 |
Why?
|
Calcium Channels, L-Type | 1 | 2006 | 117 | 0.060 |
Why?
|
Receptors, Neurotransmitter | 1 | 2004 | 17 | 0.060 |
Why?
|
Prone Position | 1 | 2024 | 30 | 0.060 |
Why?
|
Supine Position | 1 | 2024 | 38 | 0.060 |
Why?
|
Calcineurin | 1 | 2005 | 98 | 0.060 |
Why?
|
Colorado | 4 | 2019 | 4421 | 0.060 |
Why?
|
Length of Stay | 1 | 2010 | 1127 | 0.060 |
Why?
|
Multiple Chronic Conditions | 1 | 2024 | 29 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2012 | 825 | 0.060 |
Why?
|
Immunoprecipitation | 2 | 2018 | 157 | 0.060 |
Why?
|
Protein Structure, Quaternary | 1 | 2004 | 122 | 0.060 |
Why?
|
Epilepsy | 1 | 2008 | 329 | 0.060 |
Why?
|
Nitrates | 1 | 2004 | 89 | 0.060 |
Why?
|
Synaptic Transmission | 1 | 2006 | 273 | 0.060 |
Why?
|
Granuloma | 1 | 2004 | 89 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2007 | 481 | 0.050 |
Why?
|
Ventricular Function, Right | 1 | 2006 | 276 | 0.050 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 400 | 0.050 |
Why?
|
Residual Volume | 1 | 2023 | 6 | 0.050 |
Why?
|
Cell Survival | 2 | 2007 | 1086 | 0.050 |
Why?
|
Smoking Cessation | 2 | 2018 | 407 | 0.050 |
Why?
|
Monoamine Oxidase | 1 | 2003 | 27 | 0.050 |
Why?
|
Pulmonary Veins | 1 | 2024 | 98 | 0.050 |
Why?
|
Textile Industry | 1 | 2003 | 1 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2005 | 811 | 0.050 |
Why?
|
Gene Expression | 3 | 2017 | 1472 | 0.050 |
Why?
|
Minisatellite Repeats | 1 | 2003 | 40 | 0.050 |
Why?
|
Amino Acid Substitution | 2 | 2019 | 282 | 0.050 |
Why?
|
Tomography | 1 | 2023 | 24 | 0.050 |
Why?
|
Texas | 1 | 2024 | 229 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 339 | 0.050 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 2003 | 47 | 0.050 |
Why?
|
Chloride Channel Agonists | 1 | 2023 | 77 | 0.050 |
Why?
|
Muscle Spasticity | 1 | 2023 | 55 | 0.050 |
Why?
|
Unsupervised Machine Learning | 1 | 2022 | 18 | 0.050 |
Why?
|
Coenzyme A | 1 | 2022 | 8 | 0.050 |
Why?
|
Dizocilpine Maleate | 1 | 2002 | 19 | 0.050 |
Why?
|
Induced Pluripotent Stem Cells | 2 | 2016 | 221 | 0.050 |
Why?
|
Phosphatidylglycerols | 1 | 2022 | 24 | 0.050 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2002 | 50 | 0.050 |
Why?
|
3-Hydroxybutyric Acid | 1 | 2022 | 15 | 0.050 |
Why?
|
Antacids | 1 | 2022 | 16 | 0.050 |
Why?
|
Sulfur | 1 | 2022 | 51 | 0.050 |
Why?
|
Neurosecretory Systems | 1 | 2002 | 31 | 0.050 |
Why?
|
DNA, Complementary | 1 | 2002 | 270 | 0.050 |
Why?
|
Silicosis | 1 | 2002 | 27 | 0.050 |
Why?
|
Lymphocytes | 2 | 2017 | 377 | 0.050 |
Why?
|
Carnitine | 1 | 2022 | 76 | 0.050 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 2004 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 1 | 2004 | 455 | 0.050 |
Why?
|
5' Untranslated Regions | 1 | 2021 | 55 | 0.050 |
Why?
|
Research | 1 | 2005 | 416 | 0.050 |
Why?
|
Pulmonologists | 1 | 2021 | 15 | 0.050 |
Why?
|
Australia | 1 | 2022 | 243 | 0.050 |
Why?
|
Ceramides | 1 | 2022 | 112 | 0.050 |
Why?
|
Probability | 1 | 2022 | 306 | 0.050 |
Why?
|
Scoliosis | 1 | 2024 | 203 | 0.050 |
Why?
|
Oxygen | 2 | 2023 | 915 | 0.050 |
Why?
|
Hyperplasia | 1 | 2002 | 171 | 0.050 |
Why?
|
Benchmarking | 1 | 2023 | 176 | 0.050 |
Why?
|
Prefrontal Cortex | 1 | 2004 | 305 | 0.050 |
Why?
|
Belgium | 1 | 2021 | 12 | 0.050 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2021 | 27 | 0.050 |
Why?
|
Oligonucleotides, Antisense | 1 | 2021 | 113 | 0.050 |
Why?
|
Poland | 1 | 2021 | 33 | 0.050 |
Why?
|
Cell Differentiation | 3 | 2016 | 1902 | 0.050 |
Why?
|
Spain | 1 | 2021 | 34 | 0.050 |
Why?
|
Calcium-Binding Proteins | 1 | 2002 | 210 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 8 | 0.040 |
Why?
|
Protein Array Analysis | 1 | 2021 | 56 | 0.040 |
Why?
|
Finland | 1 | 2021 | 90 | 0.040 |
Why?
|
3' Untranslated Regions | 1 | 2021 | 138 | 0.040 |
Why?
|
Protective Factors | 1 | 2021 | 91 | 0.040 |
Why?
|
Germany | 1 | 2021 | 100 | 0.040 |
Why?
|
Sweden | 1 | 2021 | 93 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2024 | 672 | 0.040 |
Why?
|
New York | 1 | 2021 | 128 | 0.040 |
Why?
|
Family | 1 | 2025 | 657 | 0.040 |
Why?
|
Surface-Active Agents | 1 | 2021 | 84 | 0.040 |
Why?
|
Iceland | 1 | 2020 | 10 | 0.040 |
Why?
|
Endpoint Determination | 2 | 2011 | 76 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2021 | 110 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2007 | 1418 | 0.040 |
Why?
|
Risk Adjustment | 1 | 2021 | 79 | 0.040 |
Why?
|
Neuropsychological Tests | 2 | 2021 | 1015 | 0.040 |
Why?
|
Polymerase Chain Reaction | 1 | 2003 | 1038 | 0.040 |
Why?
|
Hemodynamics | 2 | 2021 | 1090 | 0.040 |
Why?
|
Iron | 1 | 2022 | 288 | 0.040 |
Why?
|
Mortality | 1 | 2002 | 307 | 0.040 |
Why?
|
Air | 1 | 2020 | 36 | 0.040 |
Why?
|
Canada | 1 | 2021 | 350 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2013 | 779 | 0.040 |
Why?
|
Triglycerides | 1 | 2022 | 527 | 0.040 |
Why?
|
Tobacco Smoke Pollution | 2 | 2014 | 231 | 0.040 |
Why?
|
Liquid Biopsy | 1 | 2019 | 9 | 0.040 |
Why?
|
Anthropometry | 1 | 2020 | 204 | 0.040 |
Why?
|
Image Enhancement | 1 | 2020 | 167 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2019 | 62 | 0.040 |
Why?
|
Ireland | 1 | 2019 | 27 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2019 | 184 | 0.040 |
Why?
|
Hospitals | 1 | 2024 | 637 | 0.040 |
Why?
|
Acrylamides | 1 | 2019 | 58 | 0.040 |
Why?
|
Dermatomyositis | 1 | 2019 | 26 | 0.040 |
Why?
|
Molecular Weight | 1 | 2019 | 332 | 0.040 |
Why?
|
Reference Standards | 1 | 2019 | 177 | 0.040 |
Why?
|
Fingers | 1 | 2019 | 86 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2019 | 98 | 0.040 |
Why?
|
Iowa | 1 | 2018 | 24 | 0.040 |
Why?
|
Magnetoencephalography | 1 | 2019 | 128 | 0.040 |
Why?
|
Histones | 2 | 2015 | 588 | 0.040 |
Why?
|
Dental Hygienists | 1 | 2018 | 11 | 0.040 |
Why?
|
Treatment Failure | 1 | 2019 | 340 | 0.040 |
Why?
|
Job Description | 1 | 2018 | 14 | 0.040 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2019 | 331 | 0.040 |
Why?
|
Pyrimidines | 1 | 2022 | 459 | 0.040 |
Why?
|
A549 Cells | 1 | 2018 | 59 | 0.040 |
Why?
|
Hep G2 Cells | 1 | 2018 | 61 | 0.040 |
Why?
|
Primary Cell Culture | 1 | 2018 | 160 | 0.040 |
Why?
|
Species Specificity | 1 | 2019 | 575 | 0.040 |
Why?
|
Acetylation | 1 | 2018 | 246 | 0.040 |
Why?
|
Simvastatin | 1 | 2018 | 60 | 0.040 |
Why?
|
Gene Ontology | 1 | 2017 | 51 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 284 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 249 | 0.040 |
Why?
|
Pregnancy | 1 | 2010 | 6402 | 0.040 |
Why?
|
Rheumatology | 1 | 2019 | 106 | 0.030 |
Why?
|
Patient Discharge | 1 | 2024 | 857 | 0.030 |
Why?
|
Neural Pathways | 1 | 2019 | 302 | 0.030 |
Why?
|
Netherlands | 1 | 2017 | 77 | 0.030 |
Why?
|
Death Certificates | 1 | 2017 | 30 | 0.030 |
Why?
|
Syndrome | 2 | 2009 | 341 | 0.030 |
Why?
|
Telomerase | 1 | 2019 | 233 | 0.030 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 103 | 0.030 |
Why?
|
Forecasting | 1 | 2019 | 359 | 0.030 |
Why?
|
Phosphocreatine | 1 | 2016 | 43 | 0.030 |
Why?
|
Signal Transduction | 2 | 2007 | 4925 | 0.030 |
Why?
|
Heart | 1 | 2020 | 637 | 0.030 |
Why?
|
Models, Anatomic | 1 | 2017 | 89 | 0.030 |
Why?
|
Bronchial Neoplasms | 1 | 2016 | 14 | 0.030 |
Why?
|
Tracheal Neoplasms | 1 | 2016 | 9 | 0.030 |
Why?
|
Uncertainty | 1 | 2017 | 116 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2002 | 964 | 0.030 |
Why?
|
Radiation Protection | 1 | 2016 | 36 | 0.030 |
Why?
|
Papilloma | 1 | 2016 | 48 | 0.030 |
Why?
|
Victoria | 1 | 2016 | 16 | 0.030 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2016 | 51 | 0.030 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 278 | 0.030 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2016 | 35 | 0.030 |
Why?
|
Calcium | 1 | 2002 | 1213 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2017 | 137 | 0.030 |
Why?
|
Amyloidosis | 1 | 2016 | 42 | 0.030 |
Why?
|
Inhalation | 1 | 2016 | 28 | 0.030 |
Why?
|
Asbestosis | 1 | 2015 | 13 | 0.030 |
Why?
|
Rheumatoid Factor | 1 | 2017 | 167 | 0.030 |
Why?
|
ErbB Receptors | 1 | 2019 | 607 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2017 | 185 | 0.030 |
Why?
|
Xenon Isotopes | 1 | 2015 | 3 | 0.030 |
Why?
|
Helium | 1 | 2015 | 6 | 0.030 |
Why?
|
Fluorine | 1 | 2015 | 15 | 0.030 |
Why?
|
Linkage Disequilibrium | 1 | 2016 | 257 | 0.030 |
Why?
|
Causality | 1 | 2016 | 117 | 0.030 |
Why?
|
Thoracic Surgical Procedures | 1 | 2016 | 69 | 0.030 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2015 | 37 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2018 | 582 | 0.030 |
Why?
|
Serpins | 1 | 2015 | 31 | 0.030 |
Why?
|
Markov Chains | 1 | 2015 | 117 | 0.030 |
Why?
|
Mitochondria, Muscle | 1 | 2016 | 111 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2016 | 98 | 0.030 |
Why?
|
Aconitate Hydratase | 1 | 2015 | 17 | 0.030 |
Why?
|
GTPase-Activating Proteins | 1 | 2015 | 81 | 0.030 |
Why?
|
Recurrence | 2 | 2012 | 1007 | 0.030 |
Why?
|
Software | 1 | 2020 | 608 | 0.030 |
Why?
|
Physical Examination | 1 | 2016 | 234 | 0.030 |
Why?
|
Zinc Fingers | 1 | 2015 | 44 | 0.030 |
Why?
|
K562 Cells | 1 | 2015 | 86 | 0.030 |
Why?
|
Specimen Handling | 1 | 2016 | 164 | 0.030 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2014 | 30 | 0.030 |
Why?
|
Endodeoxyribonucleases | 1 | 2015 | 67 | 0.030 |
Why?
|
Multilingualism | 1 | 2014 | 26 | 0.030 |
Why?
|
Perfusion | 1 | 2015 | 197 | 0.030 |
Why?
|
Hemochromatosis Protein | 1 | 2014 | 3 | 0.030 |
Why?
|
Acyl Coenzyme A | 1 | 2013 | 30 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2014 | 93 | 0.030 |
Why?
|
Mexico | 1 | 2014 | 190 | 0.030 |
Why?
|
Respiratory Mucosa | 1 | 2016 | 307 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2015 | 260 | 0.030 |
Why?
|
Nitrogen Isotopes | 1 | 2013 | 58 | 0.030 |
Why?
|
Propionates | 1 | 2013 | 37 | 0.030 |
Why?
|
Computer Simulation | 1 | 2018 | 943 | 0.030 |
Why?
|
Computational Biology | 1 | 2018 | 599 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2018 | 743 | 0.030 |
Why?
|
Models, Organizational | 1 | 2014 | 146 | 0.030 |
Why?
|
Isotope Labeling | 1 | 2013 | 74 | 0.030 |
Why?
|
Esters | 1 | 2013 | 74 | 0.030 |
Why?
|
Patient Safety | 1 | 2016 | 287 | 0.030 |
Why?
|
Carbon Isotopes | 1 | 2013 | 126 | 0.030 |
Why?
|
Chromosomes, Human | 1 | 2013 | 41 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2014 | 102 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 317 | 0.030 |
Why?
|
Mental Recall | 1 | 2014 | 192 | 0.030 |
Why?
|
APACHE | 1 | 2013 | 65 | 0.030 |
Why?
|
Swine | 1 | 2015 | 760 | 0.030 |
Why?
|
Health Services | 1 | 2013 | 99 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2019 | 1181 | 0.030 |
Why?
|
Observation | 1 | 2012 | 51 | 0.020 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2012 | 22 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2024 | 2483 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2012 | 53 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 1040 | 0.020 |
Why?
|
Aortography | 1 | 2012 | 51 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 589 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2013 | 216 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2012 | 114 | 0.020 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2012 | 10 | 0.020 |
Why?
|
Arthrography | 1 | 2011 | 17 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2012 | 88 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2022 | 1717 | 0.020 |
Why?
|
Graves Disease | 1 | 2012 | 35 | 0.020 |
Why?
|
Genetic Counseling | 1 | 2012 | 72 | 0.020 |
Why?
|
Herpesvirus 8, Human | 1 | 2012 | 60 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 503 | 0.020 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2012 | 111 | 0.020 |
Why?
|
Odds Ratio | 1 | 2014 | 1023 | 0.020 |
Why?
|
Pedigree | 1 | 2013 | 487 | 0.020 |
Why?
|
Exome | 1 | 2012 | 220 | 0.020 |
Why?
|
Sulfhydryl Compounds | 1 | 2013 | 187 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2012 | 504 | 0.020 |
Why?
|
Education | 1 | 2012 | 101 | 0.020 |
Why?
|
Neoplasms | 2 | 2021 | 2470 | 0.020 |
Why?
|
Caspase 1 | 1 | 2012 | 143 | 0.020 |
Why?
|
Veterans | 1 | 2002 | 1398 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2015 | 575 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 769 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 371 | 0.020 |
Why?
|
Latin America | 1 | 2011 | 88 | 0.020 |
Why?
|
Joints | 1 | 2011 | 100 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 110 | 0.020 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 149 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 106 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2012 | 224 | 0.020 |
Why?
|
Chest Pain | 1 | 2010 | 89 | 0.020 |
Why?
|
Alanine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
|
Threonine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2007 | 3215 | 0.020 |
Why?
|
Placebos | 1 | 2009 | 201 | 0.020 |
Why?
|
Administration, Oral | 1 | 2011 | 786 | 0.020 |
Why?
|
Minority Groups | 1 | 2010 | 249 | 0.020 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2008 | 14 | 0.020 |
Why?
|
Structural Homology, Protein | 1 | 2008 | 25 | 0.020 |
Why?
|
Apelin Receptors | 1 | 2007 | 4 | 0.020 |
Why?
|
Specialization | 1 | 2009 | 145 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2013 | 738 | 0.020 |
Why?
|
Apelin | 1 | 2007 | 9 | 0.020 |
Why?
|
raf Kinases | 1 | 2007 | 11 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 613 | 0.020 |
Why?
|
Velopharyngeal Insufficiency | 1 | 2006 | 10 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2007 | 66 | 0.020 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 1 | 2006 | 19 | 0.020 |
Why?
|
Catechols | 1 | 2006 | 14 | 0.020 |
Why?
|
RNA | 1 | 2013 | 883 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 169 | 0.020 |
Why?
|
Nerve Degeneration | 1 | 2006 | 47 | 0.020 |
Why?
|
Levodopa | 1 | 2006 | 29 | 0.020 |
Why?
|
Tyrosine 3-Monooxygenase | 1 | 2006 | 73 | 0.020 |
Why?
|
Parkinsonian Disorders | 1 | 2006 | 36 | 0.020 |
Why?
|
Decision Making | 1 | 2013 | 851 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2009 | 277 | 0.020 |
Why?
|
Solubility | 1 | 2006 | 235 | 0.020 |
Why?
|
Drug Industry | 1 | 2007 | 106 | 0.020 |
Why?
|
Patient Compliance | 1 | 2010 | 565 | 0.020 |
Why?
|
Cell Death | 1 | 2007 | 354 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 375 | 0.020 |
Why?
|
Medical Records | 1 | 2006 | 171 | 0.020 |
Why?
|
Tretinoin | 1 | 2006 | 130 | 0.020 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2007 | 207 | 0.020 |
Why?
|
Neuroblastoma | 1 | 2006 | 154 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2007 | 431 | 0.010 |
Why?
|
Receptor, TIE-2 | 1 | 2004 | 12 | 0.010 |
Why?
|
Models, Genetic | 1 | 2008 | 594 | 0.010 |
Why?
|
Excitatory Amino Acid Transporter 2 | 1 | 2004 | 15 | 0.010 |
Why?
|
Hypertension | 1 | 2014 | 1242 | 0.010 |
Why?
|
Cardiomegaly | 1 | 2006 | 172 | 0.010 |
Why?
|
Synucleins | 1 | 2004 | 7 | 0.010 |
Why?
|
Skin | 1 | 2009 | 725 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2006 | 317 | 0.010 |
Why?
|
Immunotherapy | 1 | 2009 | 592 | 0.010 |
Why?
|
Valine | 1 | 2004 | 81 | 0.010 |
Why?
|
Cell Count | 1 | 2004 | 314 | 0.010 |
Why?
|
Methionine | 1 | 2004 | 158 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2004 | 148 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 643 | 0.010 |
Why?
|
Protein Conformation | 1 | 2006 | 859 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2008 | 663 | 0.010 |
Why?
|
Molecular Chaperones | 1 | 2004 | 182 | 0.010 |
Why?
|
Health Services Needs and Demand | 1 | 2005 | 264 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2006 | 1033 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 752 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2010 | 1016 | 0.010 |
Why?
|
Lung Diseases, Parasitic | 1 | 2002 | 2 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2007 | 2406 | 0.010 |
Why?
|
HIV-1 | 1 | 2007 | 836 | 0.010 |
Why?
|
Hospitals, Veterans | 1 | 2002 | 255 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2004 | 497 | 0.010 |
Why?
|
Sputum | 1 | 2002 | 302 | 0.010 |
Why?
|
Risk | 1 | 2002 | 854 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 2121 | 0.010 |
Why?
|